Clinical Trials on Fractional Flow Reserve, Myocardial in Sweden

Total 10 results

University Hospital, Linkoeping

Unknown

Pilot Study of Myocardial Effects Following an Endurance Race

Myocardial Blood Flow

Sweden
French Cardiology Society

Completed

Prospective Study of Heart Failure With Preserved Left Ventricular Ejection Fraction (KaRen)

Congestive Heart Failure | Heart Failure With Preserved Ejection Fraction | Left Ventricular Ejection Fraction

Sweden, France
Uppsala University
National Heart, Lung, and Blood Institute (NHLBI); Duke Clinical Research Institute and other collaborators

Recruiting

Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction (SPIRRIT)

Heart Failure With Preserved Ejection Fraction

Sweden, United States
AstraZeneca

Completed

Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40% (ENDEAVOR)

Heart Failure With Preserved Ejection Fraction

United States, France, Netherlands, Belgium, Taiwan, Slovakia, Japan, Czechia, Hungary, Australia, Bulgaria, Poland, Russian Federation, Brazil, Denmark, Turkey, Sweden, Canada
AstraZeneca

Completed

DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction

Heart Failure With Preserved Ejection Fraction (HFpEF)

United States, Denmark, Italy, Canada, Korea, Republic of, Brazil, Slovakia, Japan, Bulgaria, South Africa, Sweden, Argentina
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF)

Heart Failure With Preserved Ejection Fraction

China, Germany, United States, Colombia, South Africa, Italy, Austria, Belgium, Croatia, Romania, Taiwan, Japan, Netherlands, Denmark, France, Israel, Spain, Switzerland, Korea, Republic of, Argentina, Canada, United Kingdom, Bulgaria, Gree... and more
Novartis Pharmaceuticals

Completed

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients (PARALLAX)

Heart Failure With Preserved Ejection Fraction

Colombia, Romania, United States, Austria, Belgium, Estonia, Turkey, Germany, Netherlands, Italy, Spain, Thailand, Argentina, France, Bulgaria, Hungary, Israel, Peru, Lithuania, Guatemala, India, Russian Federation, Denmark, Mexico, Slo... and more
Actelion
Chiltern International Ltd.; Medidata Solutions; Frontier Science & Technology... and other collaborators

Terminated

A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease (SERENADE OL)

Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

United States, United Kingdom, Israel, Austria, Russian Federation, Germany, Poland, Denmark, Argentina, Brazil, Bulgaria, France, Hungary, Romania, Sweden
Actelion

Completed

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease (SERENADE)

Heart Failure With Preserved Ejection Fraction

United States, Spain, United Kingdom, Poland, Germany, Israel, Austria, Czechia, Russian Federation, Denmark, Bulgaria, Hungary, France, Argentina, Brazil, Romania, Sweden
Novo Nordisk A/S

Completed

Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes (STEP HFpEF DM)

Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2

United States, Spain, Hungary, United Kingdom, India, Netherlands, Germany, Japan, Canada, Czechia, Argentina, Austria, Israel, Italy, Poland, Sweden

Clinical Trials on Fractional Flow Reserve, Myocardial in Sweden

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations